Ranbaxy receives US FDA approval for the manufacture and market of Cetirizine Hydrochloride

Ranbaxy Laboratories Limited (RLL) announced that it has received final approval from the US FDA to manufacture and market Cetirizine Hydrochloride Oral Solution (Allergy) and Children’s Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1 mg/mL (OTC). It is therapeutically equivalent to Children’s Zyrtec Oral Solution (Allergy) and Children’s Zyrtec Oral Solution (Hives-Relief), 1mg/mL of McNeil Consumer Healthcare. Cetirizine Hydrochloride is administered for the temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or other upper respiratory allergies. Read More

Comments

Popular posts from this blog

Databases on the FDA Website

IPEXL - New Patent Search Tool

Employee Retention – A critical issue, why..and How to solve?